(Q33389172)

26 July 2017

title

Paclitaxel, cisplatin and gemcitabine in treatment of carcinomas of unknown primary site, a phase II study (English)

1 reference

26 July 2017

1 reference

1 reference

Gedske Daugaard

4

0 references

author name string

Anne Kirstine Hundahl Møller

series ordinal

1

1 reference

26 July 2017

Karen Damgaard Pedersen

series ordinal

2

1 reference

26 July 2017

Anita Gothelf

series ordinal

3

1 reference

26 July 2017

publication date

1 May 2010

1 reference

26 July 2017

1 reference

26 July 2017

volume

49

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

423-430

1 reference

Diagnostic and therapeutic management of cancer of an unknown primary

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Carcinoma of unknown primary (CUP).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Switching benchmarks in cancer of unknown primary: from autopsy to microarray

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Treatment of patients with specific subsets of carcinoma of an unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Forty years experience of treating cancer of unknown primary

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Meta-analysis of randomized clinical trials comparing Cisplatin to Carboplatin in patients with advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Paclitaxel, gemcitabine, and cisplatin in non-resectable non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Cisplatin and gemcitabine with either vinorelbine or paclitaxel in the treatment of carcinomas of unknown primary site : results of an Italian multicenter, randomized, phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Results of a phase II study of weekly paclitaxel plus carboplatin in advanced carcinoma of unknown primary origin: a reasonable regimen for the community-based clinic?

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primary

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F02841860903544592

10.3109/02841860903544592

21 January 2018

Identifiers

DOI

1 reference

26 July 2017

1 reference